![[Updated] B-2 Spirit Bombers Struck Iranian Nuclear Sites](https://theaviationist.com/wp-content/uploads/2025/06/B2sGuam_2.jpg)
Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed
Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression, but investors appear unimpressed.
Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression, but investors appear unimpressed.
